MaxCyte, Inc. (MXCT.L)
| Previous close | 785.00 |
| Open | 800.00 |
| Bid | 790.00 x 0 |
| Ask | 800.00 x 0 |
| Day's range | 790.00 - 810.00 |
| 52-week range | 328.50 - 1,235.00 |
| Volume | 214,717 |
| Avg. volume | 147,970 |
| Market cap | 677.145M |
| Beta (5Y monthly) | 0.99 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -12.20 |
| Earnings date | 20 Sept 2021 - 24 Sept 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Is MaxCyte (LON:MXCT) Using Debt In A Risky Way?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
- Simply Wall St.
MaxCyte, Inc. (LON:MXCT) Is Expected To Breakeven In The Near Future
We feel now is a pretty good time to analyse MaxCyte, Inc.'s ( LON:MXCT ) business as it appears the company may be on...
- The Telegraph
Questor: a ‘very special company’ about to list where investors will be besotted with it
We can have no complaint about the performance of shares in MaxCyte, whose hi-tech machines help drugs firms make gene editing treatments: tipped at 370p in October last year, when we said they might be worth 500p, they closed last night at 886p and were as high as £10.40 in February. Normally we’d consider selling when a target price has been breached so comprehensively but MaxCyte finds itself in an anomalous position that it is about to rectify, a process that could do wonders for the share price. The company is based in America, has a roster of clients that are largely American and is the type of business that generates great enthusiasm among American investors – yet its shares trade on London’s Aim market. It would make far more sense to have a listing on the stock market favoured by its natural investors – the Nasdaq in New York – and the company is in the process of getting just such a listing. In the words of Richard Penny of Crux Asset Management, which owns a stake in MaxCyte, “investors in the US are besotted with gene editing – they are hugely buoyant about what they see as the third age of drug discovery” built on the decoding of the human genome 20 years ago. Besotted investors are in much shorter supply here. Britain may have a huge fund management industry but when it comes to the healthcare sector it lacks the critical mass in terms of specialist analysts, funds and brokers found in America. In fact, you could say we are positively hostile to healthcare start-ups at present. “Fire sales of the small biotech firms held in Neil Woodford’s funds depressed share prices and damaged sentiment across the board,” Mr Penny said.
